A PYMNTS Company

Nestlé agrees $2.6bn deal for Aimmune Therapeutics

By  |  August 31, 2020

Nestle will pay $2 billion to buy the remaining stake in Aimmune Therapeutics, gaining full ownership of the first US-approved peanut allergy treatment which has struggled with a slow launch due to the COVID-19 pandemic.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Nestle said on Monday its offer for Aimmune values the California-based drugmaker, in which it already has a stake of around 25.6%, at $2.6 billion.

    Aimmune’s Palforzia therapy is the only FDA-approved treatment aimed at reducing the frequency and severity of allergic reactions to peanuts in children, Nestlé said on Monday.

    The Swiss food manufacturer currently has a 25 per cent stake in Aimmune worth about $473m. It will acquire the outstanding shares it does not already own in an all-cash offer through its health subsidiary Nestlé Health Science.

    The deal will value Aimmune at $2.6bn and is expected to complete towards the end of the year, Nestlé said.

    Full Content: Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.